
|Videos|May 29, 2013
The 340B Drug Discount Program
Adam J. Fein describes how the 340B program is being exploited by many hospital systems due to a lack of oversight by government agencies.
Advertisement
In this video, Adam J. Fein describes how the 340B program is being exploited by many hospital systems due to a lack of oversight by government agencies.
For more information about Dr. Fein's controversial op-ed on 340B pricing, see
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Most Favored Nation as Drug Prices Continue to Rise
2
From Underdiagnosed to Under Control: Plozasiran and Pharmacists’ Role in FCS
3
Positive Phase 2a Trial Supports FDA Clearance of StemCyte’s HPC Therapy for Long COVID Patients
4
FDA Grants Orphan Drug Designation to Zavabresib for the Treatment of Myelofibrosis
5





















